Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 3.8% – Time to Sell?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) traded down 3.8% during mid-day trading on Thursday . The company traded as low as $8.34 and last traded at $8.46. 164,719 shares traded hands during trading, a decline of 17% from the average session volume of 199,380 shares. The stock had previously closed at $8.79.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Eupraxia Pharmaceuticals in a research report on Friday, January 9th. Lifesci Capital upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Leede Financial raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Cantor Fitzgerald lifted their price objective on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, January 15th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Eupraxia Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $14.33.

Eupraxia Pharmaceuticals Stock Performance

The firm’s fifty day simple moving average is $7.53 and its 200 day simple moving average is $6.31. The stock has a market capitalization of $304.23 million, a P/E ratio of -9.72 and a beta of 1.20.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. Analysts anticipate that Eupraxia Pharmaceuticals Inc. will post -0.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Quadrature Capital Ltd bought a new position in shares of Eupraxia Pharmaceuticals in the second quarter worth about $61,000. TCI Wealth Advisors Inc. bought a new position in Eupraxia Pharmaceuticals in the 3rd quarter valued at approximately $65,000. Integrated Wealth Concepts LLC acquired a new stake in Eupraxia Pharmaceuticals in the third quarter valued at approximately $71,000. Bank of America Corp DE grew its stake in shares of Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after buying an additional 10,059 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Eupraxia Pharmaceuticals by 593.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after acquiring an additional 16,017 shares during the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.